James C. Yao, MD, professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses key takeaways from the RADIANT-3 trial for a community oncologist.
RADIANT-3 showed significant improvement in progression-free and overall survival, including in patients with progressive disease.
After longer follow-up, the safety profile of everolimus looked consistent with what was seen before. Yao notes that a particular interesting fact about everolimus in this space is that an adverse event, stomatitis, was associated with better outcomes for patients. This finding was presented as part of a meta-analysis at the 2014 ASCO meeting.
<<< View more from NANETS